One in four Americans taking certain prescribed medicines say they would stop taking them immediately—without consulting their doctor—after seeing ads promoting lawsuits against the drugs’ manufacturers, according to a new national survey released by the U.S. Chamber Institute for Legal Reform (ILR). Read More »
Imaging3 Inc. has hired Intertek Inc. to oversee hazard analytics and U.S. Federal Drug Administration guidance protocols during the submission of the company’s Dominion VI imaging device with patented SmartScan 3D technology. Read More »
Seattle Genetics Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration using data from its recent Phase 3 Alcanza trial and two Phase 2 investigator-sponsored trials of Adcetris. Read More »
With its identity coined by the founding optometrist’s own child, RevolutionEYES’ “Little Eyes” recently opened in Carmel, Indiana, launching a pediatric eye care clinic caring for youngsters between 6 months and 13 years old. Read More »
Biohaven Pharmaceutical Holding Co. has been granted Fast Track Designation for its product candidate Trigriluzole by the FDA. Read More »
Churchill Pharmaceuticals has expanded its Commercial Leadership Team. Read More »
Addressing a recently reported nationwide antacid scarcity, QuVa Pharma Inc. — specializing in critical drug shortage products — has rallied with supplies of its own pharmaceutical quality sodium bicarbonate formulation at the ready for U.S. hospital distribution. Read More »
To combat certain types of influenza, Lannett Co. Inc. can now market its Amantadine Hydrochloride Capsules USP in 100 mg. dose form following Food and Drug Administration approval of its Abbreviated New Drug Application. Read More »
Philadelphia-based Lannett Company Inc. recently obtained approval from the U.S. Food and Drug Administration (FDA) for its generic formulation of niacin in extended-release form, with the product available in both 500-mg and 1000-mg tablet doses. Read More »
Amgen recently presented 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society, which took place in Boston. Read More »
OncoSec Medical Inc.'s pIL-12 drug, also known as tavokinogene telsaplasmid, has been given an Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
Amgen and Allergan's data supporting their Biologics License Application for ABP 215, a biosimilar candidate to Avastin (bevacizumab), will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration by July 13. Read More »
AbbVie recently announced positive top-line results from its Phase 3 Select-Next trial, which evaluated upadacitinib as a treatment for rheumatoid arthritis patients. Read More »
Navidea Biopharmaceuticals Inc. recently announced that SpePharm AG has launched Lymphoseek in the Denmark, the Netherlands and the United Kingdom. Read More »
Cigna and CVS Health have launched Cigna HealthWorks, a partnership that brings Cigna benefits to CVS Pharmacy and CVS MinuteClinic retail health care centers. Read More »
Ardsley, New York-based biopharmaceutical firm Acorda Therapeutics revealed new information derived from clinical and preclinical studies of tozadenant at the recent 2017 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Vancouver, British Columbia. Read More »
Purdue Pharma's Colace product line and Senokot tablets will now come with new packaging. Read More »
Do television ads by plaintiffs' lawyer firms hawking lawsuits over prescription drugs cause patients to cease taking their prescribed prescriptions? Read More »
Commencing a Phase 3b trial of daily oral medication ALKS 5461, Alkermes PLC will assess the treatment’s feasibility and safety for major depressive disorder patients with insufficient prior results obtained from other drugs. Read More »
The Health Affairs Blog, a vehicle for commentary on health policy and issues affecting the health care industry, recently release an article on surprise medical bills. Read More »
Alerts Sign-up
